|
1
|
Lapointe S, Perry A and Butowski NA:
Primary brain tumours in adults. Lancet. 392:432–446.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Posadas EM, Limvorasak S and Figlin RA:
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol.
13:496–511. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lee YT, Tan YJ and Oon CE: Molecular
targeted therapy: Treating cancer with specificity. Eur J
Pharmacol. 834:188–196. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Marom R, Jain M, Burrage LC, Song IW,
Graham BH, Brown CW, Stevens SJC, Stegmann APA, Gunter AT, Kaplan
JD, et al: Heterozygous variants in ACTL6A, encoding a component of
the BAF complex, are associated with intellectual disability. Hum
Mutat. 38:1365–1371. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sima X, He J, Peng J, Xu Y, Zhang F and
Deng L: The genetic alteration spectrum of the SWI/SNF complex: The
oncogenic roles of BRD9 and ACTL6A. PLoS One.
14(e0222305)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yoo AS, Staahl BT, Chen L and Crabtree GR:
MicroRNA-mediated switching of chromatin-remodelling complexes in
neural development. Nature. 460:642–646. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Son EY and Crabtree GR: The role of BAF
(mSWI/SNF) complexes in mammalian neural development. Am J Med
Genet C Semin Med Genet. 166C:333–349. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zeng Z, Yang H and Xiao S: ACTL6A
expression promotes invasion, metastasis and epithelial mesenchymal
transition of colon cancer. BMC Cancer. 18(1020)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xiao S, Chang RM, Yang MY, Lei X, Liu X,
Gao WB, Xiao JL and Yang LY: Actin-like 6A predicts poor prognosis
of hepatocellular carcinoma and promotes metastasis and
epithelial-mesenchymal transition. Hepatology. 63:1256–1271.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Meng L, Wang X, Liao W, Liu J, Liao Y and
He Q: BAF53a is a potential prognostic biomarker and promotes
invasion and epithelial-mesenchymal transition of glioma cells.
Oncol Rep. 38:3327–3334. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ji J, Xu R, Zhang X, Han M, Xu Y, Wei Y,
Ding K, Wang S, Bin Huang, Chen A, et al: Actin like-6A promotes
glioma progression through stabilization of transcriptional
regulators YAP/TAZ. Cell Death Dis. 9(517)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lee ES, Ko KK, Joe YA, Kang SG and Hong
YK: Inhibition of STAT3 reverses drug resistance acquired in
temozolomide-resistant human glioma cells. Oncol Lett. 2:115–121.
2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pan Q, Yang XJ, Wang HM, Dong XT, Wang W,
Li Y and Li JM: Chemoresistance to temozolomide in human glioma
cell line U251 is associated with increased activity of
O6-methylguanine-DNA methyltransferase and can be overcome by
metronomic temozolomide regimen. Cell Biochem Biophys. 62:185–191.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wen ZP, Zeng WJ, Chen YH, Li H, Wang JY,
Cheng Q, Yu J, Zhou HH, Liu ZZ, Xiao J and Chen XP: Knockdown ATG4C
inhibits gliomas progression and promotes temozolomide
chemosensitivity by suppressing autophagic flux. J Exp Clin Cancer
Res. 38(298)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang S, Zheng Y, He Z, Zhou W, Cheng Y and
Zhang C: SH2B1 promotes NSCLC cell proliferation through
PI3K/Akt/mTOR signaling cascade. Cancer Cell Int.
18(132)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xu XY, Zhang J, Qi YH, Kong M, Liu SA and
Hu JJ: Linc-ROR promotes endometrial cell proliferation by
activating the PI3K-Akt pathway. Eur Rev Med Pharmacol Sci.
22:2218–2225. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhu B, Ueda A, Song X, Horike SI, Yokota T
and Akagi T: Baf53a is involved in survival of mouse ES cells,
which can be compensated by Baf53b. Sci Rep.
7(14059)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sun W, Wang W, Lei J, Li H and Wu Y:
Actin-like protein 6A is a novel prognostic indicator promoting
invasion and metastasis in osteosarcoma. Oncol Rep. 37:2405–2417.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chu N, Salguero AL, Liu AZ, Chen Z,
Dempsey DR, Ficarro SB, Alexander WM, Marto JA, Li Y, Amzel LM, et
al: Akt Kinase activation mechanisms revealed using protein
semisynthesis. Cell. 174:897–907.e14. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kwiatkowska A and Symons M: Signaling
determinants of glioma cell invasion. Adv Exp Med Biol.
986:121–141. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ao R, Guan L, Wang Y and Wang JN:
Silencing of COL1A2, COL6A3, and THBS2 inhibits gastric cancer cell
proliferation, migration, and invasion while promoting apoptosis
through the PI3k-Akt signaling pathway. J Cell Biochem.
119:4420–4434. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Luo KW, Lung WY, Chun-Xie Luo XL and Huang
WR: EGCG inhibited bladder cancer T24 and 5637 cell proliferation
and migration via PI3K/AKT pathway. Oncotarget. 9:12261–12272.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Deng X, Tu Z, Xiong M, Tembo K, Zhou L,
Liu P, Pan S, Xiong J, Yang X, Leng J, et al: Wnt5a and CCL25
promote adult T-cell acute lymphoblastic leukemia cell migration,
invasion and metastasis. Oncotarget. 8:39033–39047. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ilowski M, Putz C, Weiss TS, Brand S,
Jauch KW, Hengstler JG and Thasler WE: Augmenter of liver
regeneration causes different kinetics of ERK1/2 and Akt/PKB
phosphorylation than EGF and induces hepatocyte proliferation in an
EGF receptor independent and liver specific manner. Biochem Biophys
Res Commun. 394:915–920. 2010.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Guo YY, Wu Y, Jia XW and An W: Augmenter
of liver regeneration potentiates doxorubicin anticancer efficacy
by reducing the expression of ABCB1 and ABCG2 in hepatocellular
carcinoma. Lab Invest. 97:1400–1411. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shang X, Lin K, Yu R, Zhu P, Zhang Y, Wang
L, Xu J and Chen K: Resveratrol protects the myocardium in sepsis
by activating the phosphatidylinositol 3-Kinases
(PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and
inhibiting the nuclear factor-kappaB (NF-kappaB) signaling pathway.
Med Sci Monit. 25:9290–9298. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liu W, Jing ZT, Wu SX, He Y, Lin YT, Chen
WN, Lin XJ and Lin X: A Novel AKT Activator, SC79, prevents acute
hepatic failure induced by fas-mediated apoptosis of hepatocytes.
Am J Pathol. 188:1171–1182. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Xu Y, Gao YW and Yang Y: SC79 protects
dopaminergic neurons from oxidative stress. Oncotarget.
9:12639–12648. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hegi ME, Liu L, Herman JG, Stupp R, Wick
W, Weller M, Mehta MP and Gilbert MR: Correlation of
O6-methylguanine methyltransferase (MGMT) promoter methylation with
clinical outcomes in glioblastoma and clinical strategies to
modulate MGMT activity. J Clin Oncol. 26:4189–4199. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Preusser M, Charles JR, Felsberg J,
Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C,
Heinzl H, et al: Anti-O6-methylguanine-methyltransferase (MGMT)
immunohistochemistry in glioblastoma multiforme: Observer
variability and lack of association with patient survival impede
its use as clinical biomarker. Brain Pathol. 18:520–532.
2008.PubMed/NCBI View Article : Google Scholar
|
